Case study: Optometrist says MPS II makes commercial and clinical sense


‘Macular testing improved my practice, both commercially and clinically’

In this month’s Optometry Today, optometrist Scott Mackie talks about the benefits that MPS II has brought to his two practices in Scotland.

Six months ago, he acquired the macular pigment screening device and he says that he has already made his money back several times over.

“The MPS II costs £6,000 (there’s a launch offer of £4,000 which I paid) so
essentially you would need to see 200 patients at £20.

It’s a cost-effective piece of equipment, adding value to the patient and practice.”

Download and read the article in full: AMD – is there a cure on the horizon?

Leave a Reply

Your email address will not be published. Required fields are marked *